Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Feb;172(3):384-91.
doi: 10.1111/bjh.13832. Epub 2015 Nov 18.

Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study

Thomas Prebet  1 , Zhuoxin Sun  2 , Rhett P Ketterling  3 , Amer Zeidan  1 , Peter Greenberg  4 , James Herman  5 , Mark Juckett  6 , Mitchell R Smith  7 , Lisa Malick  5 , Elisabeth Paietta  8 , Magdalena Czader  9 , Maria Figueroa  10 , Janice Gabrilove  11 , Harry P Erba  12 , Martin S Tallman  13 , Mark Litzow  14 , Steven D Gore  1 ; Eastern Cooperative Oncology Group and North American Leukemia intergroup
Affiliations
Clinical Trial

Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study

Thomas Prebet et al. Br J Haematol. 2016 Feb.

Abstract

Therapy-related myeloid neoplasms (tMN) are serious late effects of the treatment of cancer with poor response to conventional treatment. Azacitidine (AZA) has been used to treat patients with tMN but current data are retrospective. We present here 47 tMN patients prospectively enrolled as a specific cohort in the E1905 study. TheE1905 study was a randomized phase 2 study (NCT00313586) testing 10 d of AZA (50 mg/m(2) /d) +/- the histone deacetylase inhibitor entinostat (4 mg/m(2) /d PO day-3 and day-10). A total of 47 patients [29 therapy-related myelosyspastic syndrome (t-MDS) and 18 therapy-related acute myeloid leukaemia (t-AML)] were recruited to the study. 24 patients were treated with AZA monotherapy and 23 with AZA+entinostat. The median number of administered cycles was 4, significantly higher in patients treated with AZA (6 cycles vs. 3 cycles, P = 0·008). Haematological normalization rates were 46% in monotherapy and 17% in the combination arm. Median overall survivals were 13 and 6 months, respectively. The novel 50 * 10 schedule of azacitidine appears effective, with response rates, when given as single agent, comparable to those for patients with de novo MDS/AML treated on the same protocol. However, the combination of AZA and entinostat was associated with increased toxicity and could not be recommended for treatment of tMN.

Trial registration: ClinicalTrials.gov NCT00101179 NCT00313586.

Keywords: acute myeloid leukaemia; azacitidine; histone deacetylase inhibitor; myelodysplasia; therapy related.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Kaplan Meier Estimates of overall survival for the patients treated with azacitidine (solid line) and azacitidine+entinostat (broken line). Survival is defined from the initiation of therapy to death of any causes. Time interval is in months.
Fig 2
Fig 2
Comparison of overall survival in patients treated in the E1905 trials for de novo (solid line) or therapy-related (dash line) myeloid neoplasms. (A) Patients treated with azacitidine single agent (B) Patients treated with azacitidine+entinostat. Survival is defined from the initiation of therapy to death of any causes. Time interval is in months. MDS, myelodysplastic syndrome; AML, acute myeloid leukaemia.
See this image and copyright information in PMC

References

    1. Bally C, Thepot S, Quesnel B, Vey N, Dreyfus F, Fadlallah J, Turlure P, de Botton S, Dartigeas C, de Renzis B, Itzykson R, Fenaux P, Ades L. Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): a report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM) Leukemia Research. 2013;37:637–640. - PubMed
    1. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine RL, Neuberg D, Ebert BL. Clinical effect of point mutations in myelodysplastic syndromes. New England Journal of Medicine. 2011;364:2496–2506. - PMC - PubMed
    1. Blum KA, Liu Z, Lucas DM, Chen P, Xie Z, Baiocchi R, Benson DM, Devine SM, Jones J, Andritsos L, Flynn J, Plass C, Marcucci G, Chan KK, Grever MR, Byrd JC. Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation. British Journal of Haematology. 2010;150:189–195. - PMC - PubMed
    1. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nature Genetics. 1999;21:103–107. - PubMed
    1. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, Lowenberg B, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Wijermans PW, Gore S, Greenberg PL. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96:3671–3674. - PubMed

Publication types

MeSH terms

Associated data